Signatera Volumes Expected to Grow on Salesforce Expansion, Not Repeat Q2 Pace

Signatera go-forward volume trajectory: impact of Salesforce expansion and likelihood of sustained growth above current levels

What management is implicitly guiding for volumes over the next few quarters

The quarter that matters (and why it won’t automatically repeat)

• Natera reported 34 thousand clinical MRD unit sequential growth in Q2, described as the largest sequential increase to date. ¹
• Management also cautioned that Q2 sequential volume was exaggerated by several thousand units due to weather negatively impacting Q1, so Q3 is not expected to “reset” into another record on the weather-adjusted comparison. ²

Implication: near-term volume growth is expected to remain strong, but the specific magnitude of the “blowout” sequential pace in Q2 is unlikely to be repeated immediately because part of the sequential comparison benefited from the prior quarter’s weather suppression. ²¹

The company’s stated forecasting framework (linear growth model)

• For Signatera volume growth assumptions, Natera said the right framework is a linear growth model using average growth in units over the prior 4 quarters to smooth out weather, seasonality, and receiving-day variances. ²

Implication: management’s go-forward “shape” for volumes is not based on escalating step-changes every quarter; it is based on smoothed, linear growth that absorbs variability and then gradually continues upward. ²

Role of Salesforce expansion and new sales reps: how soon does it show up, and what pace is realistic?

What was observed this quarter

• Management explicitly tied the strong results to execution that is “coming off” multiple years of investment and now “hitting their stride,” including big investments in the commercial team and medical affairs, plus the halo effect after FDA approval. ³
• They also said the current results include salespeople “just come online” and that these new reps are hitting productivity, while new patient starts and new account wins were both “very strong again.” ⁴⁵¹

How management frames the incremental timing

• On the specific question of go-forward pace tied to Salesforce expansion, management did not give a numeric “ramp to X” in the excerpt, but they did emphasize two points:
  1. They can outperform the prior all-time record, but “I would not say necessarily we are going to repeat that immediately.” ³
  2. They are crossing a “tipping point” where doctors increasingly believe MRD is a core practice, and Natera’s scale (breadth of presence and sales team size) is positioned to benefit as it converts into continued adoption. ⁶

Implication: Salesforce expansion and new reps appear to be contributing (and are likely continuing to contribute), but management expects the transition from onboarding → productivity to be gradual, with continued progress rather than an immediate repeat of the Q2 sequential “record” rate. ³

Is sustained quarter-to-quarter growth beyond current levels expected?

Management’s explicit stance: outperforming records, but not necessarily “repeat immediately”

• Management referenced the prior record as around 25 thousand sequential growth units and said they can outperform that as they move forward, and that Q3 is off to a very good start. ⁷
• However, they also directly said they do not expect to set a new volume record again in Q3. ²
• They further stated that the Q2 blowout was a “blowout record” and they would not necessarily repeat it immediately. ³

Conclusion on your second question: sustained growth beyond the current quarter’s level (i.e., continuing to accelerate sequentially at Q2’s “record” step-up) is not expected in the next quarter. Instead, management points to a sustained but more normalized/linear trajectory. ²³

Putting it together: the go-forward volume “trajectory” narrative

Expected near-term trajectory (next several quarters)

• Q2 included a meaningful sequential increase (+34k units) and also benefited from Q1 weather suppression, making Q2’s sequential comparison unusually favorable. ¹²
• Natera expects to follow a linear growth model based on smoothed historical averages to handle volatility. ²
• They expect strong performance and mid-range guidance implied by “somewhere right in the middle” of prior-record territory, but not another record-setting quarter. ⁷²

Expected medium-term trajectory (as Salesforce onboarding matures and adoption deepens)

• Salesforce expansion is described as “just beginning to hit” and reps are coming online, with productivity enhancement and broader commercial execution contributing to momentum. ⁴
• Additionally, management emphasized broader adoption dynamics (“tipping point”), new patient starts, and long-tail contribution, which tends to support continued unit growth even as sequential quarters normalize. ⁶⁵

However, even with these positives, management’s own commentary indicates the Q2 sequential magnitude should not be expected to repeat immediately, and the forecasting framework implies moderation from quarter-to-quarter randomness. ²³

Final answer (directly addressing your question)

• Go-forward trajectory for Signatera volumes: The Salesforce expansion and new sales representatives appear to be contributing to momentum that is beginning to hit, supported by strong new account wins and new patient starts. ⁴⁵ But management does not expect the Q2 sequential blowout to repeat immediately; instead, it guides toward a normalized, linear growth framework that averages out weather/seasonality effects. ²³
• Is sustained quarter-to-quarter growth beyond current levels expected? Sustained growth beyond Q2’s exceptional sequential level is not expected in the immediate next quarter—management explicitly said they do not expect to set a new volume record again in Q3 and that they would not necessarily repeat the Q2 blowout immediately. ²³ Growth should continue, but the company is forecasting a more smoothed continuation rather than ongoing sequential step-ups above the Q2 pace. ²